US20100160622A1 - Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide - Google Patents

Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide Download PDF

Info

Publication number
US20100160622A1
US20100160622A1 US12/640,666 US64066609A US2010160622A1 US 20100160622 A1 US20100160622 A1 US 20100160622A1 US 64066609 A US64066609 A US 64066609A US 2010160622 A1 US2010160622 A1 US 2010160622A1
Authority
US
United States
Prior art keywords
fermentation culture
streptococcus pneumoniae
molecular weight
capsular polysaccharides
repeat units
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/640,666
Other languages
English (en)
Inventor
Jean Heather Crinean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to US12/640,666 priority Critical patent/US20100160622A1/en
Assigned to WYETH LLC reassignment WYETH LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CRINEAN, JEAN HEATHER
Publication of US20100160622A1 publication Critical patent/US20100160622A1/en
Priority to US14/845,065 priority patent/US20150376667A1/en
Priority to US15/493,806 priority patent/US20170224802A1/en
Priority to US16/912,032 priority patent/US11376315B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Definitions

  • the invention relates to methods for increasing the molecular weight of isolated Streptococcus pneumoniae capsular polysaccharides having a phosphodiester linkage between saccharide repeat units.
  • Streptococcus pneumoniae serotypes are grown to supply polysaccharides needed to produce the vaccine.
  • the cells are grown in fermentors with lysis induced at the end of the fermentation by addition of sodium deoxycholate or an alternate lysing agent.
  • the lysate broth is then harvested for downstream purification and the recovery of the capsular polysaccharide which surrounds the bacterial cells.
  • the polysaccharide is included in the final vaccine product and confers immunity in the vaccine's target population to the selected Streptococcus pneumoniae serotypes.
  • Polysaccharide size is a quality attribute assayed for in each preparation batch and must be appropriately controlled.
  • Traditional processing has involved using NaOH (sodium hydroxide) as a base titrant during fermentation.
  • NaOH sodium hydroxide
  • the use of NaOH has the advantage of being able to lower the pH of the deoxycholate lysate without foaming to remove protein and improve filtration. This material is subjected to centrifugation followed by filtration to remove most of the solids down to a 0.45 ⁇ m nominal size.
  • Such traditional processing methods result in lower molecular weight polysaccharide ( ⁇ 450 kDa) for serotypes having a phosphodiester linkage between saccharide repeat units (e.g., 6A, 6B, 19A, and 19F).
  • CO 2 is supplied to a fermentation culture of a Streptococcus pneumoniae serotype containing a phosphodiester linkage between saccharide repeat units.
  • the method includes the steps of: 1) preparing a fermentation culture of Streptococcus pneumoniae bacterial cells that produce capsular polysaccharides comprising a phosphodiester linkage between repeat units; 2) supplying CO 2 to the fermentation culture; 3) lysing the bacterial cells in the fermentation culture; and 4) isolating Streptococcus pneumoniae capsular polysaccharides from the fermentation culture, where a solution containing high molecular weight isolated Streptococcus pneumoniae capsular polysaccharides containing phosphodiester linkages between repeat units is produced.
  • fermentation cultures of Streptococcus pneumoniae bacterial cells that produce polysaccharide serotypes 19A, 6A, 19F, 6B, and combinations thereof are prepared.
  • supplying CO 2 to the fermentation culture includes adding bicarbonate ion (HCO 3 ⁇ ) to the fermentation culture, for example, adding NaHCO 3 (sodium bicarbonate) to the fermentation culture.
  • supplying CO 2 to the fermentation culture includes adding carbonate ion (CO 3 2 ⁇ ) to the fermentation culture, for example, adding Na 2 CO 3 (sodium carbonate) to the fermentation culture.
  • supplying CO 2 to the fermentation culture includes a first addition of NaHCO 3 and a second addition of Na 2 CO 3 .
  • supplying CO 2 to the fermentation culture includes overlaying the fermentation culture with CO 2 .
  • the molecular weight of the isolated Streptococcus pneumoniae capsular polysaccharide is at least 700 kDa.
  • a solution containing high molecular weight isolated Streptococcus pneumoniae capsular polysaccharides in which the polysaccharides comprise phosphodiester linkages between repeat units is provided, where the solution is produced by the method described above.
  • a method for producing a solution containing high molecular weight isolated Streptococcus pneumoniae serotype 19A capsular polysaccharides.
  • the method includes the steps of: 1) preparing a fermentation culture of Streptococcus pneumoniae bacterial cells that produce serotype 19A capsular polysaccharides; 2) supplying CO 2 to the fermentation culture; 3) lysing the bacterial cells in the fermentation culture; and 4) isolating Streptococcus pneumoniae serotype 19A capsular polysaccharides from the fermentation culture; whereby a solution containing high molecular weight isolated Streptococcus pneumoniae serotype 19A capsular polysaccharides is produced.
  • a solution containing high molecular weight isolated Streptococcus pneumoniae serotype 19A capsular polysaccharides is provided, where the solution is produced by the method described above.
  • a method for producing a solution containing high molecular weight isolated Streptococcus pneumoniae serotype 19F capsular polysaccharides.
  • the method includes the steps of: 1) preparing a fermentation culture of Streptococcus pneumoniae bacterial cells that produce serotype 19F capsular polysaccharides; 2) supplying CO 2 to the fermentation culture; 3) lysing the bacterial cells in the fermentation culture; and 4) isolating Streptococcus pneumoniae serotype 19F capsular polysaccharides from the fermentation culture; whereby a solution containing high molecular weight isolated Streptococcus pneumoniae serotype 19F capsular polysaccharides is produced.
  • a solution containing high molecular weight isolated Streptococcus pneumoniae serotype 19F capsular polysaccharides is provided, where the solution is produced by the method described above.
  • a method for producing a solution containing high molecular weight isolated Streptococcus pneumoniae serotype 6A capsular polysaccharides.
  • the method includes the steps of: 1) preparing a fermentation culture of Streptococcus pneumoniae bacterial cells that produce serotype 6A capsular polysaccharides; 2) supplying CO 2 to the fermentation culture; 3) lysing the bacterial cells in the fermentation culture; and 4) isolating Streptococcus pneumoniae serotype 6A capsular polysaccharides from the fermentation culture; whereby a solution containing high molecular weight isolated Streptococcus pneumoniae serotype 6A capsular polysaccharides is produced.
  • a solution containing high molecular weight isolated Streptococcus pneumoniae serotype 6A capsular polysaccharides is provided, where the solution is produced by the method described above.
  • a method for producing a solution containing high molecular weight isolated Streptococcus pneumoniae serotype 6B capsular polysaccharides.
  • the method includes the steps of: 1) preparing a fermentation culture of Streptococcus pneumoniae bacterial cells that produce serotype 6B capsular polysaccharides; 2) supplying CO 2 to the fermentation culture; 3) lysing the bacterial cells in the fermentation culture; and 4) isolating Streptococcus pneumoniae serotype 6B capsular polysaccharides from the fermentation culture; whereby a solution containing high molecular weight isolated Streptococcus pneumoniae serotype 6B capsular polysaccharides is produced.
  • a solution containing high molecular weight isolated Streptococcus pneumoniae serotype 6B capsular polysaccharides is provided, where the solution is produced by the method described above.
  • FIG. 1 shows the optical density (OD), base and glucose levels during the fermentation phase with Na 2 CO 3 as titration base from laboratory studies at 3 L scale. Base in grams is divided by 10 for plotting purposes.
  • FIG. 2 shows the optical density (OD), base and glucose levels during the fermentation phase with NaOH as titration base from laboratory studies at 3 L scale. Base in grams is divided by 10 for plotting purposes.
  • FIG. 3 shows total protein and polysaccharide results at different pH adjustments for alternate base feeds of Na 2 CO 3 or NaOH.
  • Streptococcus pneumoniae are Gram-positive, lancet shaped cocci that are usually seen in pairs (diplococci), but also in short chains or as single cells. They grow readily on blood agar plates with glistening colonies and display alpha hemolysis unless grown anaerobically where they show beta hemolysis.
  • the cells of most pneumococcal serotypes have a capsule which is a polysaccharide coating surrounding each cell. This capsule is a determinant of virulence in humans, as it interferes with phagocytosis by preventing antibodies from attaching to the bacterial cells.
  • pneumococcal capsular serotypes identified, with the 23 most common serotypes accounting for approximately 90% of invasive disease worldwide.
  • the pneumococcal polysaccharide coat can confer a reasonable degree of immunity to Streptococcus pneumoniae in individuals with developed or unimpaired immune systems, but a conjugated protein with polysaccharide allows for an immune response in infants and elderly who are also most at risk for pneumococcal infections.
  • the pneumococcal cells are grown in fermentors with lysis induced at the end of the fermentation. The lysate broth is then harvested for downstream purification and the recovery of the capsular polysaccharides.
  • Polysaccharide size is a quality attribute assayed for in each preparation batch and must be appropriately controlled.
  • the molecular weight for serotypes having a phosphodiester linkage between saccharide repeat units (e.g., 6A, 6B, 19A, and 19F) is affected by parameters of the fermentation process.
  • the methods of the present invention allow for the recovery of high molecular weight capsular polysaccharides from cellular Streptococcus pneumoniae lysates containing serotypes having a phosphodiester linkage between saccharide repeat units, such as serotype 6A, serotype 6B, serotype 19A, serotype 19F, and combinations thereof.
  • the concentration of HySoy and choice of base titrant were modified in an attempt to modify final polysaccharide yields and molecular weights.
  • Four fermentation schemes were tested. The first used a baseline NaOH process with 28 g/L HySoy. The second used 20% sodium carbonate as the base titrant and 20 g/L HySoy.
  • the third combined advantages of the first two approaches by introducing carbonate through the batching of sodium bicarbonate and using a mixed NaOH/carbonate base titrant.
  • the fourth approach used carbonate as the base titrant with a 10 mM bicarbonate addition to bolster growth.
  • Minimizing the amount of Na 2 CO 3 by using a blend of NaOH and Na 2 CO 3 as a pH titrant provided the molecular weight size benefits of Na 2 CO 3 while eliminating foaming and filtration problems due to the sudden release of large amounts of CO 2 .
  • the use of 20% Na 2 CO 3 (w/v) as the base titrant with a 10 mM NaHCO 3 addition to bolster growth (fourth approach) produced consistent, high molecular weight polysaccharides at high yield.
  • the present invention thus provides improved methods for the recovery of high molecular weight capsular polysaccharides from cellular Streptococcus pneumoniae lysates containing serotypes having a phosphodiester linkage between saccharide repeat units.
  • CO 2 is supplied to a fermentation culture of a Streptococcus pneumoniae serotype containing a phosphodiester linkage between saccharide repeat units.
  • Exemplary Streptococcus pneumoniae serotypes containing a phosphodiester linkage between saccharide repeat units include serotypes 6A, 6B, 19A, and 19F.
  • a method for producing a solution containing high molecular weight isolated Streptococcus pneumoniae capsular polysaccharides that comprise phosphodiester linkages between repeat units includes the steps of: 1) preparing a fermentation culture of Streptococcus pneumoniae bacterial cells that produce capsular polysaccharides comprising a phosphodiester linkage between repeat units; 2) supplying CO 2 to the fermentation culture; 3) lysing the bacterial cells in the fermentation culture; and 4) isolating Streptococcus pneumoniae capsular polysaccharides from the fermentation culture; whereby a solution containing high molecular weight isolated Streptococcus pneumoniae capsular polysaccharides with phosphodiester linkages between repeat units is produced.
  • the present invention relates to a solution containing high molecular weight isolated Streptococcus pneumoniae capsular polysaccharides with phosphodiester linkages between repeat units, where the solution is produced by the method described above.
  • high molecular weight refers to molecular weights that are at least about 480 kDa, about 490 kDa, about 500 kDa, about 510 kDa, about 520 kDa, about 525 kDa, about 550 kDa, about 575 kDa, about 600 kDa, about 625 kDa, about 650 kDa, about 675 kDa, about 700 kDa, about 725 kDa, about 750 kDa, about 775 kDa, about 800 kDa, about 825 kDa, about 850 kDa, about 875 kDa, about 900 kDa, about 925 kDa, about
  • supplying CO 2 to the fermentation culture includes adding bicarbonate ion (HCO 3 ⁇ ) to the fermentation culture, for example, adding NaHCO 3 to the fermentation culture.
  • HCO 3 additions of 5-50 mM can be used, such as 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, or 50 mM.
  • supplying CO 2 to the fermentation culture includes adding carbonate ion (CO 3 2 ⁇ ) to the fermentation culture, for example, adding Na 2 CO 3 to the fermentation culture.
  • Na 2 CO 3 additions of 0.1 M-2.0 M can be used, such as 0.1 M, 0.2 M, 0.4 M, 0.6 M, 0.7 M, 0.9 M, 1.0 M, 1.5 M, 1.8 M, or 2.0 M.
  • a weight/volume (w/v) equivalent can also be used, such as 5% (w/v) Na 2 CO 3 , 10% (w/v) Na 2 CO 3 or 20% (w/v) Na 2 CO 3 .
  • supplying CO 2 to the fermentation culture includes a first addition of NaHCO 3 and a second addition of Na 2 CO 3 to the fermentation culture.
  • supplying CO 2 to the fermentation culture includes overlaying the fermentation culture with CO 2 .
  • CO 2 overlays of 5%-100% can be used, for example, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
  • the bacterial cells may be lysed using any lytic agent.
  • a “lytic agent” is any agent that aids in cell wall breakdown and release of autolysin which causes cellular lysis including, for example, detergents.
  • detergent refers to any anionic or cationic detergent capable of inducing lysis of bacterial cells. Representative examples of such detergents for use within the methods of the present invention include deoxycholate sodium (DOC), N-lauryl sarcosine (NLS), chenodeoxycholic acid sodium, and saponins.
  • DOC deoxycholate sodium
  • NLS N-lauryl sarcosine
  • chenodeoxycholic acid sodium and saponins.
  • the lytic agent used for lysing bacterial cells is DOC.
  • DOC is the sodium salt of the bile acid deoxycholic acid, which is commonly derived from biological sources such as cows or oxen.
  • DOC activates the LytA protein, which is an autolysin that is involved in cell wall growth and division in Streptococcus pneumoniae .
  • the LytA protein has choline binding domains in its C-terminal portion, and mutations of the lytA gene are known to produce LytA mutants that are resistant to lysis with DOC.
  • the lytic agent used for lysing bacterial cells is a non-animal derived lytic agent.
  • Non-animal derived lytic agents for use within the methods of the present invention include agents from non-animal sources with modes of action similar to that of DOC (i.e., that affect LytA function and result in lysis of Streptococcus pneumoniae cells).
  • non-animal derived lytic agents include, but are not limited to, analogs of DOC, surfactants, detergents, and structural analogs of choline, and may be determined using procedures as described in the Experimental section herein below.
  • the non-animal derived lytic agent is selected from the group consisting of decanesulfonic acid, tert-octylphenoxy poly(oxyethylene)ethanols (e.g. Igepal® CA-630, CAS #: 9002-93-1, available from Sigma Aldrich, St. Louis, Mo.), octylphenol ethylene oxide condensates (e.g. Triton® X-100, available from Sigma Aldrich, St.
  • NLS N-lauryl sarcosine sodium
  • lauryl iminodipropionate sodium dodecyl sulfate, chenodeoxycholate, hyodeoxycholate, glycodeoxycholate, taurodeoxycholate, taurochenodeoxycholate, and cholate.
  • the non-animal derived lytic agent is NLS.
  • Streptococcus pneumoniae capsular polysaccharides are isolated using standard techniques known to those skilled in the art. For example, following fermentation of bacterial cells that produce Streptococcus pneumoniae capsular polysaccharides, the bacterial cells are lysed to produce a cell lysate. The capsular polysaccharides may then be isolated from the cell lysate using purification techniques known in the art, including the use of centrifugation, precipitation, ultra-filtration, and column chromatography (See, for example, U.S. Patent App. Pub. Nos. 20060228380, 20060228381, 20070184071, 20070184072, 20070231340, and 20080102498).
  • Selected Streptococcus pneumoniae serotypes were grown to supply polysaccharides needed to produce vaccines for active immunization against invasive disease caused by Streptococcus pneumoniae due to capsular serotypes included in the vaccine.
  • the cells were grown in fermentors with lysis induced at the end of the fermentation.
  • the lysate broth was then harvested for downstream purification and the recovery of the capsular polysaccharides. Because polysaccharide size is a quality attribute assayed for in each preparation batch, polysaccharide size must be appropriately controlled.
  • the molecular weight for serotypes having a phosphodiester linkage between saccharide repeat units was found to be affected by parameters of the fermentation process.
  • the following example describes studies relating to the supply of CO 2 during fermentation of Streptococcus pneumoniae serotypes having a phosphodiester linkage between repeat units to improve polysaccharide molecular weight.
  • Two 2 L seed bottles containing 1 L of HYS media were inoculated with Type 19A or Type 6A frozen seed stocks and incubated at 36° C. without shaking for approximately 6-8 hours. Inoculation of the fermentors was performed with a volume of 100 mL ( ⁇ 5.2% v/v) aliquoted from a bottle with an OD 600 between 0.3-0.9 and pH between 4.75-5.60. The fermentation temperature and pH were controlled at the desired setpoints. The standard conditions of 36° C., 1 L/min air overlay, pH controlled to 7 and agitation of 75 rpm were used. Two impellers were placed at the low and middle positions on the agitator shaft.
  • a bottle containing the appropriate base titrant (3 N NaOH, 3 N NaOH blended with various concentrations of NaHCO 3 , 3 N NaOH blended with various concentrations of Na 2 CO 3 and NaHCO 3 , and 20% Na 2 CO 3 ) was hooked up for automatic pH control.
  • the fermentors were sampled at various time points for external pH, OD 600 , glucose, polysaccharide, and protein. The runs were terminated when the glucose concentration was near depletion, or no increase in OD over time was noted.
  • the cellular density of the fermentation broth was determined by reading the absorbance of the samples at 600 nm using a Shimadzu (Columbia, Md.) UV-1601 (2 nm bandwidth) or Spectronics (Westbury, N.Y.) Genesys 5 spectrophotometer (5 nm bandwidth).
  • the unit was blanked with the HYS medium diluted with de-ionized (DI) water to match the dilution required of the sample.
  • DI de-ionized
  • Glucose levels were determined by centrifuging out the cells and using the supernatant straight or 3 ⁇ diluted with DI water. The samples were analyzed on a Nova Biomedical (Waltham, Mass.) BioProfile 400.
  • Samples were taken at the final fermentation reading and treated with 12% sodium deoxycholate (DOC) to a concentration of 0.13% (w/v) and gently agitated. They were held between 8-24 hours at 5° C. then pH adjusted to 5.0 with 50% acetic acid to precipitate out most of the DOC and protein. After another hold interval of 12-24 hours at 5° C., the samples were centrifuged (14000 rpm, Sorvall (Thermo Fisher Scientific, Waltham, Mass.) SS34 rotor, 10 min at 15° C.). The pH of the supernatant was adjusted to 6.0.
  • DOC sodium deoxycholate
  • HPLC-SEC high-performance size exclusion chromatography
  • Protein levels were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) methods well known in the art (see, e.g., Walker, J. M. “The Protein Protocols Handbook” Totowa, N.J.: Humana Press (2002)).
  • SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
  • the filtered cell lysate (supernatant) as prepared above was aliquoted into microfuge tubes at 65 ⁇ L/tube. Additions of reducing agent (10 ⁇ L dithiothreitol (DTT)) and NuPAGE® (Invitrogen, Carlsbad, Calif.) 4 ⁇ lithium dodecyl sulfate (LDS) sample buffer (25 ⁇ L) were made to each sample.
  • DTT dithiothreitol
  • NuPAGE® Invitrogen, Carlsbad, Calif.
  • Fermentation samples of 1-2 liters were treated with 12% sodium DOC to a concentration of 0.13% (w/v) with agitation at 200 rpm. Samples were held between 8-24 hours at either 5° C. or 20° C. The samples were then pH adjusted to 5.0 or 6.6 with 50% acetic acid to precipitate out most of the DOC and protein. After another hold interval of 12-24 hours at 5° C., the samples were centrifuged (11000 rpm, Sorvall (Thermo Fisher Scientific, Waltham, Mass.) SLA-3000 rotor, 15 min at 10° C.).
  • the supernatant samples were then pH adjusted to 6.0 with 3 N NaOH, and filtered using 0.45 ⁇ m Millipore (Billerica, Mass.) MP60 filters.
  • the samples were then subjected to a modified purification process consisting of 100K molecular weight cut-off (MWCO) diafiltration (5 ⁇ concentration followed by 7.5 ⁇ diafiltration with DI water), 0.1% HB precipitation, and carbon filtration.
  • MWCO molecular weight cut-off
  • the purified material was then subjected to Multi Angle Laser Light Scattering (MALLS) analysis.
  • MALLS Multi Angle Laser Light Scattering
  • the lysate was held overnight with agitation at ambient temperature (22° C.). After the lysate hold, the lysate was pH titrated through a range from unadjusted to 4.5 with samples pulled at various pH setpoints. These samples were held overnight at ambient temperature prior to being processed and analyzed for polysaccharide and protein concentrations. The OD, base and glucose levels during the fermentation phase are shown in FIG. 1 and FIG. 2 . The major difference was a higher final OD for the carbonate run.
  • the effect of post DOC lysate pH adjustment on total protein levels was also examined, and is shown in FIG. 3 .
  • the lower pH levels reduced the protein load in cell free broth for both the NaOH run and the Na 2 CO 3 run.
  • the lower pH ( ⁇ 6.6) had no negative impact on the polysaccharide yield.
  • the fermentation analysis results served as an indication that the NaOH base feed was an acceptable alternative to the process using the Na 2 CO 3 base feed during fermentation, but produced lower yields than what was obtained with the Na 2 CO 3 feed.
  • a set of fermentations at the 3 L scale were performed to determine if the base titrant, HySoy concentration and pH hold step affected serotype 19A molecular weight.
  • the molecular weight determination was performed using MALLS assay following the modified purification process. Results are shown in Table 1. For serotype 6A, only the base titrant was evaluated. Results are shown in Table 2.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
US12/640,666 2008-12-18 2009-12-17 Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide Abandoned US20100160622A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/640,666 US20100160622A1 (en) 2008-12-18 2009-12-17 Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide
US14/845,065 US20150376667A1 (en) 2008-12-18 2015-09-03 Method for controlling streptococcus pneum0niae polysaccharide molecular weight using carbon dioxide
US15/493,806 US20170224802A1 (en) 2008-12-18 2017-04-21 Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide
US16/912,032 US11376315B2 (en) 2008-12-18 2020-06-25 Method for controlling Streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13857008P 2008-12-18 2008-12-18
US12/640,666 US20100160622A1 (en) 2008-12-18 2009-12-17 Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/845,065 Continuation US20150376667A1 (en) 2008-12-18 2015-09-03 Method for controlling streptococcus pneum0niae polysaccharide molecular weight using carbon dioxide

Publications (1)

Publication Number Publication Date
US20100160622A1 true US20100160622A1 (en) 2010-06-24

Family

ID=41666441

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/640,666 Abandoned US20100160622A1 (en) 2008-12-18 2009-12-17 Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide
US14/845,065 Abandoned US20150376667A1 (en) 2008-12-18 2015-09-03 Method for controlling streptococcus pneum0niae polysaccharide molecular weight using carbon dioxide
US15/493,806 Abandoned US20170224802A1 (en) 2008-12-18 2017-04-21 Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide
US16/912,032 Active US11376315B2 (en) 2008-12-18 2020-06-25 Method for controlling Streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide

Family Applications After (3)

Application Number Title Priority Date Filing Date
US14/845,065 Abandoned US20150376667A1 (en) 2008-12-18 2015-09-03 Method for controlling streptococcus pneum0niae polysaccharide molecular weight using carbon dioxide
US15/493,806 Abandoned US20170224802A1 (en) 2008-12-18 2017-04-21 Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide
US16/912,032 Active US11376315B2 (en) 2008-12-18 2020-06-25 Method for controlling Streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide

Country Status (19)

Country Link
US (4) US20100160622A1 (pl)
EP (1) EP2385981B1 (pl)
JP (2) JP5789514B2 (pl)
KR (1) KR101307703B1 (pl)
CN (1) CN102257127B (pl)
AU (1) AU2009335824B2 (pl)
BR (1) BRPI0923165A8 (pl)
CA (1) CA2743708C (pl)
DK (1) DK2385981T3 (pl)
ES (1) ES2749952T3 (pl)
HK (1) HK1163737A1 (pl)
HU (1) HUE046859T2 (pl)
IL (1) IL213215A (pl)
MX (1) MX346071B (pl)
PL (1) PL2385981T3 (pl)
PT (1) PT2385981T (pl)
RU (1) RU2524436C2 (pl)
SI (1) SI2385981T1 (pl)
WO (1) WO2010080484A1 (pl)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100158953A1 (en) * 2008-12-18 2010-06-24 Wyeth Llc Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight
US20200181565A1 (en) * 2018-12-06 2020-06-11 Inventprise, Llc Bacterial Growth on Non-Animal Derived Media

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR058707A1 (es) 2005-12-22 2008-02-20 Glaxosmithkline Biolog Sa Vacuna, procedimiento para fabricarla y su uso
CA2757620C (en) 2009-04-30 2016-04-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2011151841A1 (en) * 2010-05-31 2011-12-08 Panacea Biotec Limited Fermentation process for streptococcus pneumoniae
AU2017388891A1 (en) 2016-12-30 2019-07-04 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
KR20190108583A (ko) 2017-01-31 2019-09-24 머크 샤프 앤드 돔 코포레이션 다당류-단백질 접합체 제조 방법
KR20240011879A (ko) 2017-02-24 2024-01-26 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체의 면역원성의 증진
WO2019050813A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
CN117018172A (zh) 2017-09-07 2023-11-10 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
CN107746825A (zh) * 2017-11-30 2018-03-02 成都欧林生物科技股份有限公司 利于肺炎链球菌快速增殖的培养基
CN108004160A (zh) * 2017-11-30 2018-05-08 成都欧林生物科技股份有限公司 含有中药材的菌种培养基的制备方法
CN111683678B (zh) 2017-12-06 2024-01-26 默沙东有限责任公司 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
JP7506605B6 (ja) 2018-04-30 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌莢膜多糖類担体タンパク質複合体の製造方法
JP7397000B2 (ja) 2018-04-30 2023-12-12 メルク・シャープ・アンド・ドーム・エルエルシー 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法
JP7275277B2 (ja) 2018-12-19 2023-05-17 メルク・シャープ・アンド・ドーム・エルエルシー ストレプトコッカス・ニューモニエ多糖－タンパク質コンジュゲートを含む組成物およびその使用方法

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115058A (en) * 1977-10-03 1978-09-19 Fmc Corporation Aromatic sulfonic anhydrides as peroxygen activators
US4221906A (en) * 1979-03-19 1980-09-09 American Cyanamid Company Stabilization of pneumococcal polysaccharides
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
US5623057A (en) * 1991-01-28 1997-04-22 Merck & Co., Inc. Pneumococcal polysaccharide conjugate vaccine
US5714354A (en) * 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
US5847112A (en) * 1991-01-28 1998-12-08 Merck & Co., Inc. Process for making capsular polysaccharides from Streptococcus pneumoniae
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US6743610B2 (en) * 2001-03-30 2004-06-01 The University Of Chicago Method to produce succinic acid from raw hydrolysates
US20060228380A1 (en) * 2005-04-08 2006-10-12 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20060228381A1 (en) * 2005-04-08 2006-10-12 Wyeth Separation of contaminants from Streptococcus pneumoniae polysaccharide by pH manipulation
US20060294620A1 (en) * 2002-10-31 2006-12-28 Gray Kevin A Amylases, nucleic acids encoding them and methods for making and using them
US20070065460A1 (en) * 2003-09-11 2007-03-22 Nederlands Vaccininstituut Process for producing a capsular polysaccharide for use in conjugate vaccines
US20070184071A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070231340A1 (en) * 2005-04-08 2007-10-04 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20080102498A1 (en) * 2006-10-10 2008-05-01 Wyeth Methods for the separation of streptococcus pneumoniae type 3 polysaccharides
US20080286838A1 (en) * 2007-03-23 2008-11-20 Wyeth Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
US20100158953A1 (en) * 2008-12-18 2010-06-24 Wyeth Llc Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1115210A (en) 1977-11-28 1981-12-29 Dennis J. Carlo Pneumococcal vaccine
US4242501A (en) 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
FR2495939B1 (fr) 1980-12-11 1985-10-11 Merieux Inst Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5656206A (en) * 1995-06-14 1997-08-12 Transitions Optical, Inc. Substituted naphthopyrans
PT1268844E (pt) * 2000-03-16 2009-11-03 Philadelphia Children Hospital Modulação da produção de polissacáridos capsulares de pneumococos
US7320874B2 (en) * 2003-07-08 2008-01-22 Aventis Pasteur Sa Assaying the teichoic acids of gram+ bacteria
GB0522303D0 (en) 2005-11-01 2005-12-07 Chiron Srl Culture method
JP5285431B2 (ja) * 2005-12-28 2013-09-11 ザ ユーエイビー リサーチ ファウンデイション 肺炎球菌血清型
EP2167121B1 (en) * 2007-06-26 2015-09-02 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115058A (en) * 1977-10-03 1978-09-19 Fmc Corporation Aromatic sulfonic anhydrides as peroxygen activators
US4221906A (en) * 1979-03-19 1980-09-09 American Cyanamid Company Stabilization of pneumococcal polysaccharides
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
US5623057A (en) * 1991-01-28 1997-04-22 Merck & Co., Inc. Pneumococcal polysaccharide conjugate vaccine
US5847112A (en) * 1991-01-28 1998-12-08 Merck & Co., Inc. Process for making capsular polysaccharides from Streptococcus pneumoniae
US5714354A (en) * 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US6743610B2 (en) * 2001-03-30 2004-06-01 The University Of Chicago Method to produce succinic acid from raw hydrolysates
US20060294620A1 (en) * 2002-10-31 2006-12-28 Gray Kevin A Amylases, nucleic acids encoding them and methods for making and using them
US20070065460A1 (en) * 2003-09-11 2007-03-22 Nederlands Vaccininstituut Process for producing a capsular polysaccharide for use in conjugate vaccines
US20060228381A1 (en) * 2005-04-08 2006-10-12 Wyeth Separation of contaminants from Streptococcus pneumoniae polysaccharide by pH manipulation
US20060228380A1 (en) * 2005-04-08 2006-10-12 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184071A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070231340A1 (en) * 2005-04-08 2007-10-04 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7718791B2 (en) * 2005-04-08 2010-05-18 Wyeth Llc Separation of contaminants from Streptococcus pneumoniae polysaccharide by pH manipulation
US20080102498A1 (en) * 2006-10-10 2008-05-01 Wyeth Methods for the separation of streptococcus pneumoniae type 3 polysaccharides
US20080286838A1 (en) * 2007-03-23 2008-11-20 Wyeth Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
US20100158953A1 (en) * 2008-12-18 2010-06-24 Wyeth Llc Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Aldrich Catalog (1996) page 1328. *
English translation of Wang et al. J. Gansu Sci. (2004) 16(3): 40-44 *
Protocol Online http://www.protocol-online.org/biology-forums/posts/29642.html downloaded 8/9/2014. *
Pujar et al. Biopolymers (2004) 75: 71-84. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100158953A1 (en) * 2008-12-18 2010-06-24 Wyeth Llc Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight
US8795689B2 (en) 2008-12-18 2014-08-05 Wyeth Llc Method for controlling Streptococcus pneumoniae serotype 19A polysaccharide molecular weight
US20200181565A1 (en) * 2018-12-06 2020-06-11 Inventprise, Llc Bacterial Growth on Non-Animal Derived Media

Also Published As

Publication number Publication date
CN102257127A (zh) 2011-11-23
ES2749952T3 (es) 2020-03-24
HUE046859T2 (hu) 2020-03-30
WO2010080484A1 (en) 2010-07-15
RU2524436C2 (ru) 2014-07-27
JP5789514B2 (ja) 2015-10-07
PT2385981T (pt) 2019-10-28
CA2743708C (en) 2018-01-09
JP2015144614A (ja) 2015-08-13
EP2385981B1 (en) 2019-09-04
RU2011124143A (ru) 2013-01-27
BRPI0923165A2 (pt) 2016-02-10
MX346071B (es) 2017-03-02
IL213215A (en) 2017-08-31
CN102257127B (zh) 2014-01-01
SI2385981T1 (sl) 2019-11-29
AU2009335824A1 (en) 2010-07-15
PL2385981T3 (pl) 2020-01-31
US20150376667A1 (en) 2015-12-31
EP2385981A1 (en) 2011-11-16
JP2012512659A (ja) 2012-06-07
JP6095715B2 (ja) 2017-03-15
KR101307703B1 (ko) 2013-09-11
AU2009335824B2 (en) 2013-07-04
KR20110091548A (ko) 2011-08-11
US20170224802A1 (en) 2017-08-10
IL213215A0 (en) 2011-07-31
MX2011006431A (es) 2011-07-19
CA2743708A1 (en) 2010-07-15
US20200323974A1 (en) 2020-10-15
HK1163737A1 (en) 2012-09-14
BRPI0923165A8 (pt) 2017-09-12
US11376315B2 (en) 2022-07-05
DK2385981T3 (da) 2019-10-21

Similar Documents

Publication Publication Date Title
US11376315B2 (en) Method for controlling Streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide
US8795689B2 (en) Method for controlling Streptococcus pneumoniae serotype 19A polysaccharide molecular weight
JP6872649B2 (ja) 莢膜Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ多糖の生産のための短縮された精製プロセス
EP3466982B1 (en) Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation

Legal Events

Date Code Title Description
AS Assignment

Owner name: WYETH LLC,NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CRINEAN, JEAN HEATHER;REEL/FRAME:024077/0849

Effective date: 20100303

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION